Clinical trials: Immunologic Deficiency Syndrome
Infection, Human Immunodeficiency Virus
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
This study is a 48-week, Phase IIIb, randomly assigned, open-label, active-controlled, multicenter, parallel group, non-inferiority study.
- Trial name
- NCT02105987
- Testing
- ABC/DTG/3TC FDC, Ongoing cART regimen
- Where
- 103 sites in United States, Canada and 1 more
- Volunteers
- 555 people
- Sponsor
- ViiV Healthcare
Alcohol Dependence, Problem Drinking
Alcohol Pharmacotherapy for HIV+ Prisoners
This is a randomized controlled trial of injectable intramuscular naltrexone (XR-NTX) versus intramuscular placebo among HIV-infected prisoners meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition…
- Conditions
- Alcohol Dependence, Problem Drinking, Hazardous Drinking, Human Immunodeficiency Virus
- Trial name
- INSPIRE (NCT01077310)
- Testing
- Vivitrol- Intramuscular naltrexone (depot-formulation)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Yale University
HIV Infections
Atazanavir and Lamivudine for Treatment Simplification
Objectives of the study: 1. To verify the safety of the study treatment, defined as the persistent control of the virus' replication at 48 weeks after the simplification to lamivudine + atazanavir with ritonavir. 2.
- Trial name
- AtLaS (NCT00885482)
- Testing
- Lamiduvine (Epivir), Atazanavir (Reyataz), Ritonavir (Norvir)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Catholic University of the Sacred Heart
HIV Infections
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
To assess the efficacy of enfuvirtide (Fuzeon) added to HAART compared to treatment with HAART alone in achieving and maintaining viral load suppression.
- Trial name
- INTENSE (NCT00487188)
- Testing
- Enfuvirtide, Highly active antiretroviral treatment (HAART)
- Where
- 39 sites in United States, Canada and 8 more
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
Human Immunodeficiency Virus Infection, Sexually Transmitted Diseases
Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men
Sub-Saharan Africa has about 10% of the world's population, but was home to more than 60% of all people living with HIV in 2003.
- Trial name
- NCT01490359
- Testing
- Men Making a Difference HIV/STD Risk Reduction Intervention, Health Promotion Control
- Volunteers
- 1,181 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
HIV Infections
HIV Non Occupational Post-Exposure Prophylaxis (PEP)
This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.
- Trial name
- NCT00594646
- Testing
- TRUVADA + Raltegravir
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Fenway Community Health
HIV Infections
Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy
The purpose of this study is to evaluate the maternal and infant safety of the dapivirine (DPV) vaginal ring (VR) and daily oral Truvada in HIV-uninfected pregnant women and their infants.
- Trial name
- NCT03965923
- Testing
- Dapivirine (DPV) Vaginal Ring (VR), Truvada Tablet
- Where
- 4 sites in Malawi, South Africa and 2 more
- Volunteers
- 1,104 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Metabolic Syndrome X
Lifestyle Modification and Metformin Use in the Treatment of HIV
A healthy diet and exercise have improved the health of people without human immunodeficiency virus (HIV) who have Metabolic Syndrome.
- Trial name
- NCT00399360
- Testing
- Metformin, Lifestyle Modification
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
HIV Infections, Mild Cognitive Impairment
Feasibility of the Mindfulness-Based Stress Reduction Intervention for Black Women Living With HIV Supplement
In our Supplement Aim we will conduct a two-arm randomized pilot test of the adapted intervention compared to a usual care control group among 30 African American/Black women with HIV (15/arm) to assess the feasibility and…
- Trial name
- NCT04984681
- Testing
- Mindfulness, Usual Care
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Human Immunodeficiency Virus
Development of Method of Fructose Identification in Urine to Detect the Viral Infection
The goal of this research is the attempt to implement a new research method based on modern electrochemistry successes, in particular the development of the polarographic method of fructose and fructose diphosphate identification…
- Trial name
- NCT01638312
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Human Immunodeficiency Virus
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
The primary purpose of this study is to determine the pharmacokinetic properties (what the body does to maraviroc) and to determine a suitable dosing schedule of maraviroc in HIV-1 infected children and adolescents.
- Trial name
- NCT00791700
- Testing
- Maraviroc
- Where
- 41 sites in United States, Brazil and 7 more
- Volunteers
- 103 people
- Sponsor
- ViiV Healthcare
HIV Infections
Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir
Once-daily nucleotide/nucleoside reverse transcriptase inhibitor (NtRTI/NRTI) combinations form the backbone of many regimens. Although efficacy data exists between tenofovir and the pyrimidine analogues (i.e.
- Trial name
- NCT00214890
- Testing
- Tenofovir, Abacavir
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Diego
HIV Infections
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
This is a 90-day medication adherence study testing the HiDO is an automated AI-driven direct observation medication adherence platform, which is a 510K-exempt, Class I medical device with 24 people with HIV/AIDS, ages 18 to 55…
- Trial name
- NCT05454514
- Testing
- HiDO medication adherence platform, Automated Medication Platform with Video Observation, Time on Task
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Charles Gellman
HIV Infections
A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy
This research study is being done to find out how the immune system in the small intestines improves after taking antiretroviral (anti-HIV) medications.
- Trial name
- NCT00870363
- Testing
- maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor), maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor), efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Smoking Cessation, Smoking
Smoking Cessation Pilot for People Living With HIV (PLWH)
The overall goal of this pilot study is to evaluate the feasibility of the Lumme smartphone app for smoking cessation in people living with HIV (PLWH) and evaluate its effect on smoking cessation.
- Conditions
- Smoking Cessation, Smoking, Smoking Behaviors, Smoking Reduction
- Trial name
- NCT04808609
- Testing
- Lumme mobile phone application, Standard of Care
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Columbia University
HIV Infections
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects
Maraviroc (UK-427,857), a selective and reversible CCR5 co-receptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes).
- Trial name
- NCT00098748
- Testing
- Optimized Background Therapy (OBT), maraviroc (UK-427,857)
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 190 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults
The purpose of this study was to evaluate the efficacy of GSK3640254 + DTG relative to lamivudine (3TC) + DTG in treatment-naïve adult participants living with human immunodeficiency virus (HIV)-1.
- Trial name
- DYNAMIC (NCT04900038)
- Testing
- GSK3640254, Dolutegravir, Lamivudine capsules
- Where
- 44 sites in United States, Argentina and 8 more
- Volunteers
- 85 people
- Sponsor
- ViiV Healthcare
HIV Infections, HIV-1
TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.
The purpose of this trial is to compare the effectiveness, safety and tolerability of TMC278 given at a dose of 25 mg once daily versus efavirenz (EFV) at a dose of 600 mg once daily, when combined with a fixed background regimen…
- Conditions
- HIV Infections, HIV-1, Human Immunodeficiency Virus Type 1
- Trial name
- NCT00540449
- Testing
- TMC278, Efavirenz
- Where
- 92 sites in United States, Argentina and 18 more
- Volunteers
- 694 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Human Immunodeficiency Virus-type 1 Infection
A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment
The purpose of this study is to demonstrate noninferiority (a new treatment is equivalent to standard treatment) in terms of the percentage of patients who have plasma human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid…
- Trial name
- SALIF (NCT01709084)
- Testing
- Rilpivirine, Efavirenz, Tenofovir disoproxil fumarate
- Where
- 18 sites in Cameroon, Kenya and 4 more
- Volunteers
- 426 people
- Sponsor
- Janssen-Cilag International NV
HIV Infections
Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)
The researchers are involved in a phase II, randomized, two-arm study, comparing the efficacy, safety, and tolerability of open-label ritonavir (RTV)-enhanced darunavir with Truvada to a 5-drug multi-class regimen including…
- Trial name
- NCT00525733
- Testing
- darunavir 800 mg, FTC 200 mg/TDF 300mg, Maraviroc
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rockefeller University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.